Emerging targeted therapies for melanoma treatment (review) - Wikidata - wikimedia - TriplyDB

Emerging targeted therapies for melanoma treatment (review)

Emerging targeted therapies for melanoma treatment (review)

http://www.wikidata.org/entity/Q26829997

about

Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility Detailed simulation of cancer exome sequencing data reveals differences and common limitations of variant callers.Integrated analysis of multidimensional omics data on cutaneous melanoma prognosis.Standardization of A375 human melanoma models on chicken embryo chorioallantoic membrane and Balb/c nude mice Transient TNF regulates the self-renewing capacity of stem-like label-retaining cells in sphere and skin equivalent models of melanoma.Combined Tumor Cell-Based Vaccination and Interleukin-12 Gene Therapy Polarizes the Tumor Microenvironment in Mice Sur8/Shoc2 promotes cell motility and metastasis through activation of Ras-PI3K signaling.FMNL2/FMNL3 formins are linked with oncogenic pathways and predict melanoma outcome.MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma Rendomab B4, a monoclonal antibody that discriminates the human endothelin B receptor of melanoma cells and inhibits their migration.Genetics and epigenetics of melanoma.Hmgb1 inhibits Klotho expression and malignant phenotype in melanoma cells by activating NF-κB.NF‑κB inhibition is associated with OPN/MMP‑9 downregulation in cutaneous melanoma.Computational modeling in melanoma for novel drug discovery.A Misleading Anamnesis: Learning To Suspect.Late Onset Achromatic Melanoma Arising in a Giant Congenital Melanocytic Nevus.Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps.Metastatic Melanoma: Treatment and Survival in the US after the Introduction of Ipilimumab and Vemurafenib.FOXP3 expression is modulated by TGF‑β1/NOTCH1 pathway in human melanoma.

P2860

Q28078465-4E1F2D56-2120-4B4F-9DDE-8C5C73BD99B0 Q30833698-5C539746-B89E-4237-B54F-A63EE98C0B98 Q31089944-086DECBD-32D1-4D26-A129-FAC22F0002C3 Q33857709-F1BB9E59-2B61-477B-B86A-755A33AA5AEB Q34233871-E035D249-7D5A-43F7-891A-1B7A202D4D64 Q36249314-0614D9DD-59D4-4B2C-8E8D-ECFAAF6E24EA Q36545077-261E10E4-8227-47EE-B7A5-2A9D15660662 Q36873816-762EBB57-07B6-4E8E-8872-7E404D2B9536 Q37062481-91888CCB-3B9E-4252-8508-925863014CBB Q37327310-C66FDECB-0609-4F45-BB45-7962B2F5EA3C Q37406812-B14F7F6C-8000-4651-964E-3D83D2B1DBF6 Q37697068-3A9EFC7D-DEEC-46EA-A473-02C782A4F6E1 Q37707767-B534A041-4CE5-47FC-A0EF-683E250696D3 Q38798578-9D57F07D-DCE8-4661-8B70-8DFA19E3EB80 Q40102783-30FCDA1F-EA2D-4DA7-AF57-A70A5C85A91C Q41179869-FDE8BFD2-C256-4DE6-B7F8-D506C21E8F10 Q48128794-CC875234-D0E3-4AC8-8F1A-7DD76E6DB1A6 Q51071853-D1C63F75-28E6-431E-BA27-B74569A19B92 Q55001270-D0082FB8-FA74-4D55-B9E7-670F8C901C3D

P2860

Emerging targeted therapies for melanoma treatment (review)

http://www.wikidata.org/entity/Q26829997

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Emerging targeted therapies for melanoma treatment (review)

@ast

Emerging targeted therapies for melanoma treatment (review)

@en

Emerging targeted therapies for melanoma treatment (review)

@nl

type

label

Emerging targeted therapies for melanoma treatment (review)

@ast

Emerging targeted therapies for melanoma treatment (review)

@en

Emerging targeted therapies for melanoma treatment (review)

@nl

prefLabel

Emerging targeted therapies for melanoma treatment (review)

@ast

Emerging targeted therapies for melanoma treatment (review)

@en

Emerging targeted therapies for melanoma treatment (review)

@nl

P1433

Q26829997-5EF32DEC-A68C-44A1-91CB-8844EA200843

P1476

Q26829997-5910224A-7115-4348-B6FF-9B2F03B8A740

P2093

Q26829997-1B269DCE-08EE-4D2B-9DA4-E2D2CB08F4C0

Q26829997-35143C21-8729-434D-8D83-FC19E69AF5F3

Q26829997-52F5AD70-0D00-47B8-9B9F-7F483260AABC

Q26829997-6D368DF8-C2FB-47AB-94E0-723C1D1E9AE9

Q26829997-FD44752D-F034-40F2-BF73-2BEBD3804555

P275

Q26829997-6504D351-34EB-45D4-A832-FCAD2C00820D

P2860

Q26829997-02FCCA3F-AFA4-4AA9-B67A-EF3DB5268B54

Q26829997-03A785CC-FE26-4E0C-BB78-75BDE2EF029F

Q26829997-03EDF313-3421-49DF-B9F0-443BF834BA47

Q26829997-04C922FA-C303-4207-973D-8D760676426D

Q26829997-069FC55B-B882-419C-8B28-9106C3D86792

Q26829997-08E3C621-14C7-4AA0-9831-C1A744B33CBC

Q26829997-0B30A7FB-1A73-4E4E-82C5-752AA7EFEFBA

Q26829997-0BFCE154-9D2B-4B0B-8626-C6FF81360B6E

Q26829997-0C3ECC9C-91C7-4A95-AA12-D71445D3ECCD

Q26829997-16CC321A-CA6C-4A49-8D61-90A00F1ACAF3

P304

Q26829997-04600D8A-0FE5-43F0-ACC5-C1F0C031E0EE

P31

Q26829997-EB560684-E980-49BF-9D02-9EC1ECB00ED2

P3181

Q26829997-35FCDB93-3FDB-4AD8-90E4-6CCB06A6E022

P356

Q26829997-EB7FE9B0-AA02-4D58-A894-34D7772CDAB3

P407

Q26829997-14229D5E-0894-4229-BD9C-F80444563E20

P433

Q26829997-DFC815D7-AC2A-44E7-9F9F-FB14D83CDD96

P478

Q26829997-34CA9BD1-3CE5-4205-A89E-E1DA625196EA

P50

Q26829997-3282154A-04E0-4DA2-8781-9DCF4A50A011

Q26829997-3C3ECCFB-0187-47CB-8C63-C7D19DE81605

Q26829997-840AA135-3789-4A9C-9452-2890B1159D16

Q26829997-A54DCA31-B7B9-4FB0-AAA2-0AF84D015878

Q26829997-B57C8053-51BC-4E55-8EBA-FF1470D6A1D3

P5008

Q26829997-9FB105D2-F740-4375-8C84-2685B098AAFC

P577

Q26829997-ADC89898-CEA8-46CF-9343-71D7C4914714

P5875

Q26829997-23DC79B0-4780-45E0-BBD5-B4F47128085E

P698

Q26829997-78338362-2AF4-433B-B085-89D57EC3407E

P921

Q26829997-7E9DB6C0-C7AD-4A56-BAA5-961EFC0DE0EF

Q26829997-8B9459A9-3FD4-443A-BD5C-E97FCA7FEE16

Q26829997-E1DF2A6E-09BB-47B2-BACE-7F31EB6E928E

P932

Q26829997-1DAACAA0-DCC2-49E5-8BA6-11BDE357F0C1

P3181

P356

P1433

International Journal of Oncology

P1476

Emerging targeted therapies for melanoma treatment (review)

@en

P2093

Angela Russo

http://www.w3.org/2001/XMLSchema#string

Bartolomea Ficili

http://www.w3.org/2001/XMLSchema#string

Claudio Guarneri

http://www.w3.org/2001/XMLSchema#string

Franca Maria Pezzino

http://www.w3.org/2001/XMLSchema#string

Salvatore Travali

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

A landscape of driver mutations in melanoma

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma

MEK1 mutations confer resistance to MEK and B-RAF inhibition.

P304

516-524

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2109750

http://www.w3.org/2001/XMLSchema#string

P356

10.3892/IJO.2014.2481

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

45

http://www.w3.org/2001/XMLSchema#string

P50

Demetrios Spandidos

James A. McCubrey

Saverio Candido

P5008

P577

2014-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262885006

http://www.w3.org/2001/XMLSchema#string

P698

24899250

http://www.w3.org/2001/XMLSchema#string

P921

P932

4091965

http://www.w3.org/2001/XMLSchema#string